Markets:

Overview

News

Currencies

International

Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

18.07 +0.07 (+0.36%)

Streaming Delayed Price Updated: 12:33 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 ↗

March 28, 2024

ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Atara Biotherapeutics: Q4 Earnings Insights ↗

March 28, 2024

Via Benzinga

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

March 28, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 18, 2024

Via Benzinga

Where Atara Biotherapeutics Stands With Analysts ↗

November 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 06, 2024

Via Benzinga

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

February 29, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

February 28, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

February 14, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗

February 05, 2024

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 02, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 02, 2024

Via Benzinga

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

January 31, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 15, 2024

Via Benzinga

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

January 08, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

January 08, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 25, 2023

Via Benzinga

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 22, 2023

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Via Benzinga

Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

December 22, 2023

Shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) shares rose sharply in pre-market trading after the company announced a new $515 million contract with a U.S. government customer.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 21, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 20, 2023

Via Benzinga

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

December 20, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

December 11, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 07, 2023

Via Benzinga

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 01, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

November 29, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

November 22, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

November 10, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

All News about Atara Biotherapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today